Type-1 Collagen differentially alters β-catenin accumulation in primary Dupuytren's Disease cord and adjacent palmar fascia cells
© Vi et al; licensee BioMed Central Ltd. 2009
Received: 29 January 2009
Accepted: 19 June 2009
Published: 19 June 2009
Dupuytren's Disease (DD) is a debilitating contractile fibrosis of the palmar fascia characterised by excess collagen deposition, contractile myofibroblast development, increased Transforming Growth Factor-β levels and β-catenin accumulation. The aim of this study was to determine if a collagen-enriched environment, similar to in vivo conditions, altered β-catenin accumulation by primary DD cells in the presence or absence of Transforming Growth Factor-β.
Primary DD and patient matched, phenotypically normal palmar fascia (PF) cells were cultured in the presence or absence of type-1 collagen and Transforming Growth Factor-β1. β-catenin and α-smooth muscle actin levels were assessed by western immunoblotting and immunofluorescence microscopy.
DD cells display a rapid depletion of cellular β-catenin not evident in patient-matched PF cells. This effect was not evident in either cell type when cultured in the absence of type-1 collagen. Exogenous addition of Transforming Growth Factor-β1 to DD cells in collagen culture negates the loss of β-catenin accumulation. Transforming Growth Factor-β1-induced α-smooth muscle actin, a marker of myofibroblast differentiation, is attenuated by the inclusion of type-1 collagen in cultures of DD and PF cells.
Our findings implicate type-1 collagen as a previously unrecognized regulator of β-catenin accumulation and a modifier of TGF-β1 signaling specifically in primary DD cells. These data have implications for current treatment modalities as well as the design of in vitro models for research into the molecular mechanisms of DD.
Dupuytren's contracture, or Dupuytren's Disease, (DD) [1–3] is a common, benign palmar fibromatosis of unknown etiology that results in finger contracture and loss of hand function. The most widely accepted treatment is surgical resection of the disease cord, an approach associated with prolonged post-operative rehabilitation and high recurrence rates [4, 5]. Recently, minimally invasive treatment alternatives such as clostridial collagenase injection [6, 7] and needle aponeurotomy [8–10] have gained popularity. While these approaches require relatively little post-treatment rehabilitation, their long-term efficacy and disease recurrence rates relative to fasciectomy are yet to be clearly established.
We and others have identified dysregulated genes in primary cultures of DD cells  or DD cord and nodule tissue [12–14]. Many of these gene transcripts encode extracellular matrix (ECM)-associated proteins, including several types of collagen. Biochemical analyses of DD cord demonstrate the abundance of type I and III collagen [15–17] with type IV and other collagens present to a lesser extent .
As with many fibroproliferative conditions, DD is associated with alterations in Transforming Growth Factor (TGF)-β signaling pathways [19–25] and this cytokine promotes both collagen production and contractile myofibroblast development in this disease [26, 27]. TGF-β1 has been shown to stimulate fibroblast proliferation by inducing β-catenin accumulation and transactivation of the Tcf/Lef transcription complex during normal and abnormal cutaneous wound repair [28–30]. Primary DD fibroblasts are reported to have an enhanced sensitivity to TGF-β1 signaling  and we have previously documented that surgically resected DD cord contains elevated levels of β-catenin , implying that TGF-β induced β-catenin accumulation may promote fibroblast proliferation in DD. We have also previously demonstrated that β-catenin levels are altered by isometric tension and ECM-cellular interactions in three dimensional collagen culture in DD cells relative to palmar fascia (PF) cells derived from the same patients [32–34]. These findings suggest that isometric tension during FPCL contraction, collagen interactions or both differentially regulate β-catenin accumulation in these cultures and that changes in β-catenin levels may also be a component of increased contractility that DD cells display relative to patient matched PF cells.
To discern the contribution of collagen to the regulation of cellular β-catenin levels, we have cultured DD and PF cells on type-1 collagen-coated trays in the absence of three-dimensional contraction with or without exogenous addition of TGF-β1. We hypothesized that the presence of type-1 collagen in DD cell cultures, designed to more closely recapitulate in vivo conditions, would differentially regulate the responsiveness of DD and/or PF cells to environmental stimuli such as TGF-β1 resulting in changes in β-catenin accumulation.
Clinical Specimen collection
Surgically resected Dupuytren's Disease (DD) cord and small samples of phenotypically normal palmar fascia tissue (PF) were collected from patients undergoing primary surgical resection of DD at the Hand and Upper Limb Centre, London, Ontario. None of these patients were being treated for recurrent disease. All subjects provided written informed consent under institutional review board approval and specimens were collected with the approval of the University of Western Ontario Research Ethics Board for Health Sciences Research involving Human Subjects (HSREB protocol # 08222E).
Primary cell culture
Primary cells were isolated from surgically resected DD cord and adjacent, phenotypically normal palmar fascia using routine tissue culture practice as previously described . In brief, tissues were aseptically dissected and pressed onto 100 mm culture dishes in α-MEM-medium supplemented with 10% fetal bovine serum (FBS, Invitrogen Corporation, Carlsbad, CA) and 1% antibiotic-antimycotic solution (Sigma-Aldrich, St Louis, MO). Once cellular outgrowths from the tissue fragments were evident, the cells are passaged by routine trypinization. Primary cells isolated by this procedure invariably display a fibroblastic morphology. Six DD cord-derived cell cultures and six patient-matched PF-derived cell cultures were used for these experiments.
For in vitro culture on collagen, collagen fibers were mechanically extracted from rat tail tendons (adapted from ), placed under UV light overnight and then incubated in sterile acetic acid, with mechanical stirring for 7 days at 4°C. Undissolved collagen fibers were removed by centrifugation at 10,000 × g at 4°C for two hours. Collagen concentration was determined using the Sircol Collagen Quantification assay (Biocolor Ltd., Carrickfergus, UK). For tissue culture, collagen monolayers were cast in 6-well tissue culture trays with each well containing 800 μl collagen and 200 μl of the neutralization solution (2 parts 0.34 N NaOH and 3 parts 10× Waymouth media) to a final concentration of 1.9 mg/ml. Following collagen polymerization, primary cells were added in α-MEM, 10% FBS and 1% antibiotic-antimycotic solution at 37°C in 5% CO2 for 72 hours. After 72 hours, media was aspirated from each well and cells were treated as described in the text.
Recombinant Transforming Growth Factor (TGF)β-1 (R&D Systems, Minneapolis, MN) was included in cell cultures as described in the text.
Cells cultured on collagen coated trays were washed with PBS prior to treatment with Collagenase XI (Sigma-Aldrich, St. Louis, MO) to dislodge the adherent cells. The cells were pelleted by centrifugation and cell lysates were prepared in PhosphoSafe protein Extraction Buffer in accordance with the manufacturer's instruction. Cell grown on tissue culture plastic trays were lysed directly in PhosphoSafe protein Extraction Buffer. After centrifuging the extracts to remove insoluble material, equivalent protein quantities were determined by BCA analysis, subjected to immunoblotting and probed with antibodies against β-catenin (BD Biosciences, Mississauga ON), α smooth muscle actin (AbCam, Cambridge MA) and β Actin (Labvision, Fremont, CA). Immunoblot analysis was carried out using standard procedures and immunoreactivity was visualized using Enhanced Chemiluminescence (ECL). A minimum of three and a maximum of six DD and patient-matched PF cell cultures were used for these experiments. All immunoblots were repeated a minimum of three times and representative blots are shown. Intensity of signals relative to β-actin controls were calculated by densitometry using ImageJ software http://rsbweb.nih.gov/ij/index.html and averages of arbitrary densitometry units and standard error of data obtained from at least 3 independent experiments were calculated. Paired t-tests were used to assess the significance of differences between groups. Results were deemed significant when p < 0.05.
Cells cultured on collagen were fixed with 4% paraformaldehyde in PBS for 20 min and permeabilized with 0.1% Triton X-100 in PBS for 15 min. The preparations were then blocked with 5% non-fat skim milk for 1 hr in PBS. Cells were stained for DNA (DAPI) actin stress fibers (Alexa 488 phallodin, Molecular Probes, Eugene OR), and β-catenin (TRITC-conjugated anti-β-catenin, BD Biosciences, Mississauga ON). All images were captured using a CoolSnap digital camera attached to an IX81 Olympus Inverted Microscope. Three DD and three patient-matched PF cell cultures were used for these experiments. All immunofluorescence studies were repeated three times and representative images are shown.
Collagen culture differentially regulates β-catenin accumulation in primary DD and PF cells
Collagen culture modifies TGFβ-1-induced β-catenin accumulation and α-smooth muscle actin expression in DD and PF cells
The data reported here emphasize the importance of recognizing the disease environment as a major contributor to changes in gene expression and cellular phenotype. We have utilized in vitro models that mimic one aspect of the in vivo DD environment, excess collagen deposition, and show that this single addition results in rapid depletion of cytoplasmic b-catenin levels and markedly alters DD cell responses to TGFβ-1.
These studies utilized primary fibroblastic cells derived from surgically resected DD cord tissue and patient-matched, phenotypically normal palmar fascia. While several studies have indicated that nodular tissue is inherently more "biologically active" than cord tissue in vivo [14, 31, 37, 38], many have also noted that primary cells derived from either of these structures are very similar in appearance and responsiveness to TGFβ [31, 37]. These observations correlate with more recent studies indicating that cells derived from primary nodule and cord have very similar gene expression profiles . As Dupuytren's Disease cords are surgically resected much more frequently than nodules, we have utilized these abundant and biologically useful tissues to allow us to compare multiple matched pairs of primary cells in this study.
The collagen used for these experiments, extracted from rat tail tendon, is primarily type 1 [40, 41] while DD cord has been reported to contain a mixture of type I and III collagens [15–17] with type IV and other collagens present to a lesser extent . DD cord collagen is also reported to feature increased levels of hydroxylysine and reducible cross-links, biochemical changes associated with connective-tissue repair . As collagen type III is an α1(III)3 homotrimer, while type I collagen is usually either an α 1(I)2 and α 2(I) heterotrimer or an α 1(I)3 homotrimer , it is likely that our culture system, while closer to in vivo conditions than plastic culture trays, does not recapitulate some aspects of the DD cord environment. Future studies will include determining if addition of type-III and other collagens into our in vitro model system further modifies any of the disease-specific responses identified in this report.
Previous reports have indicated that primary DD cells are more sensitive to a subset of cytokines including TGFβ-1 than phenotypically normal control cells [31, 44]. We have shown that a collagen-rich environment alters the responses of DD cells to exogenous TGFβ-1, a well recognized cytokine component of DD cord in vivo [26, 27, 45]. Contractile fibroblasts can activate latent TGFβ in the ECM , suggesting the possibility that simultaneous activation of mechano-receptors and latent, ECM-associated TGFβ may induce contractility in a positive feed-back loop in this fibrosis. It is possible that the altered induction of α-SMA and β-catenin by TGFβ-1 treatment reported here may reflect changes in substrate stiffness between tissue-culture plastic and collagen surfaces, thereby altering concurrent mechano-receptor and TGFβ receptor activation.
TGFβ-1 signaling has been reported to utilize the combinatorial effects of other signaling molecules to direct fibroblasts toward either a proliferative or a contractile phenotype . In our experimental system, type-1 collagen was shown to modify cellular responses to exogenous TGFβ-1, specifically increasing β-catenin accumulation in DD cells and attenuating the increase in α-SMA levels in both DD and PF cells. Overall, these data are consistent with type-1 collagen modifying TGFβ-1 induced proliferation and contractile myofibroblast differentiation in DD.
It is currently unclear to what extent collagen acts to sequester TGFβ-1, thereby decreasing its bioavailability, or modifies cellular signaling cascades resulting in altered cellular responses. Integrins are the primary mediators of signals from the extra-cellular matrix that affect cellular gene expression or changes in morphology [48, 49]. We speculate that novel combinations of integrins in DD cells may mediate the increased sensitivity of DD cells to their collagen-enriched environment. TGFβ1 can induce α5β1 expression in other cell types [50, 51] and DD cord myofibroblasts are reported to express higher levels of α5β1 integrins than cells in surrounding tissues [52, 53]. Type 1 collagen/β1 integrin interactions have been reported to alter cytoplasmic β-catenin accumulation in tumor cells through tyrosine kinase-mediated disruption of adherens junctions . We have previously reported tyrosine phosphorylated β-catenin accumulation in collagen-rich DD cord tissue , indicating that tyrosine kinase-mediated adherens junction disruption may contribute to the cytoplasmic β-catenin evident in DD tissue. Cytoplasmic β-catenin levels are regulated through serine-9 phosphorylation and inactivation of Glycogen Synthase kinase (GSK)3β in the canonical pathway rather than through changes in transcriptional activity of CTNNB1, the gene encoding β-catenin . Studies are currently underway to assess both tyrosine phosphorylated β-catenin levels and Glycogen Synthase kinase (GSK)3β activity in DD and PF cells grown on collagen in the presence or absence of TGFβ1 to clarify the source(s) of β-catenin in DD.
Current treatment for DD includes surgical resection of the disease cord, clostridial collagenase injection and needle aponeurotomy. These procedures differ in the amount of type-1 collagen-rich extra-cellular matrix remains in situ after treatment. While it is premature to translate the in vitro data reported here to treatment recommendations, it is possible that treatment that disrupt mechanical tension and deplete disease-associated collagen may have beneficial effects on disease progression and recurrence beyond mechanical disruption of the disease cord alone. In contrast, treatment that disrupt the DD cord and relieve mechanical tension but do not alter the level of disease-associated collagen within the fascia may allow DD-associated fibroblasts to maintain their disease phenotype, potentially resulting in higher rates of disease progression and recurrence.
In summary, these findings implicate type-1 collagen as a regulator of DD cell phenotype and emphasize the importance of modeling fibroproliferative diseases in general, and DD in particular, in culture systems that include ECM components of the in vivo disease environment.
We gratefully acknowledge the support of the Institute of Musculoskeletal Health and Arthritis (IMHA), Canadian Institutes of Health Research (CIHR) summer studentships for LV and AN. BSG would like to acknowledge the UWO Dept of Surgery for a Clinician Scientist Award, a UWO Dean's salary support Award and a CIHR short-term Clinician Scientist Award. This study was supported by grants from the Canadian Society for Surgery of the Hand (BSG, DBO), Plastic Surgery Education Fund (BSG, DBO), the Lawson Health Research Institute's Internal Research Fund (DBO) and a CIHR operating grant MOP 84247 to DBO and BSG.
- Gudmundsson KG, Jonsson T, Arngrimsson R: Guillaume Dupuytren and finger contractures. Lancet. 2003, 362 (9378): 165-168. 10.1016/S0140-6736(03)13871-8.View ArticlePubMedGoogle Scholar
- Saar JD, Grothaus PC: Dupuytren's disease: an overview. Plast Reconstr Surg. 2000, 106 (1): 125-134. quiz 135-126.PubMedGoogle Scholar
- Thurston AJ: Dupuytren's disease. J Bone Joint Surg Br. 2003, 85 (4): 469-477. 10.1302/0301-620X.85B4.14215.View ArticlePubMedGoogle Scholar
- Gudmundsson KG, Arngrimsson R, Jonsson T: Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren's disease. Scand J Rheumatol. 2001, 30 (1): 31-34. 10.1080/030097401750065292.View ArticlePubMedGoogle Scholar
- Hindocha S, Stanley JK, Watson S, Bayat A: Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg [Am]. 2006, 31 (10): 1626-1634. 10.1016/j.jhsa.2006.09.006.View ArticleGoogle Scholar
- Badalamente MA, Hurst LC, Hentz VR: Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg [Am]. 2002, 27 (5): 788-798. 10.1053/jhsu.2002.35299.View ArticleGoogle Scholar
- Badalamente MA, Hurst LC: Enzyme injection as nonsurgical treatment of Dupuytren's disease. J Hand Surg [Am]. 2000, 25 (4): 629-636. 10.1053/jhsu.2000.6918.View ArticleGoogle Scholar
- Foucher G, Medina J, Navarro R: Percutaneous needle aponeurotomy: complications and results. J Hand Surg [Br]. 2003, 28 (5): 427-431.View ArticleGoogle Scholar
- Cheng HS, Hung LK, Tse WL, Ho PC: Needle aponeurotomy for Dupuytren's contracture. J Orthop Surg (Hong Kong). 2008, 16 (1): 88-90.Google Scholar
- Trojian TH, Chu SM: Dupuytren's disease: diagnosis and treatment. Am Fam Physician. 2007, 76 (1): 86-89.PubMedGoogle Scholar
- Satish L, Laframboise WA, O'Gorman DB, Johnson S, Janto B, Gan BS, Baratz ME, Hu FZ, Post JC, Ehrlich GD: Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture. BMC Med Genomics. 2008, 1: 10-10.1186/1755-8794-1-10.View ArticlePubMedPubMed CentralGoogle Scholar
- Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF: Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology. 2004, 64 (2): 399-404. 10.1016/j.urology.2004.04.006.View ArticlePubMedGoogle Scholar
- Lee LC, Zhang AY, Chong AK, Pham H, Longaker MT, Chang J: Expression of a Novel Gene, MafB, in Dupuytren's Disease. J Hand Surg [Am]. 2006, 31 (2): 211-218. 10.1016/j.jhsa.2005.09.007.View ArticleGoogle Scholar
- Rehman S, Salway F, Stanley JK, Ollier WE, Day P, Bayat A: Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg [Am]. 2008, 33 (3): 359-372. 10.1016/j.jhsa.2007.11.010.View ArticleGoogle Scholar
- Bailey AJ, Sims TJ, Gabbiani G, Bazin S, LeLous M: Collagen of Dupuytren's disease. Clin Sci Mol Med. 1977, 53 (5): 499-502.PubMedGoogle Scholar
- Arkkila PE, Koskinen PJ, Kantola IM, Ronnemaa T, Seppanen E, Viikari JS: Dupuytren's disease in type I diabetic subjects: investigation of biochemical markers of type III and I collagen. Clin Exp Rheumatol. 2000, 18 (2): 215-219.PubMedGoogle Scholar
- Bazin S, Le Lous M, Duance VC, Sims TJ, Bailey AJ, Gabbiani G, D'Andiran G, Pizzolato G, Browski A, Nicoletis C: Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur J Clin Invest. 1980, 10 (1): 9-16. 10.1111/j.1365-2362.1980.tb00003.x.View ArticlePubMedGoogle Scholar
- Berndt A, Kosmehl H, Katenkamp D, Tauchmann V: Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology. 1994, 62 (2): 55-58. 10.1159/000163879.View ArticlePubMedGoogle Scholar
- Bowley E, O'Gorman DB, Gan BS: Beta-catenin signaling in fibroproliferative disease. J Surg Res. 2007, 138 (1): 141-150. 10.1016/j.jss.2006.07.026.View ArticlePubMedGoogle Scholar
- Montgomery E, Lee JH, Abraham SC, Wu TT: Superficial fibromatoses are genetically distinct from deep fibromatoses. Mod Pathol. 2001, 14 (7): 695-701. 10.1038/modpathol.3880374.View ArticlePubMedGoogle Scholar
- Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ: Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997, 151 (2): 329-334.PubMedPubMed CentralGoogle Scholar
- Nagase H, Miyoshi Y, Horii A, Aoki T, Petersen GM, Vogelstein B, Maher E, Ogawa M, Maruyama M, Utsunomiya J: Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients. Hum Mutat. 1992, 1 (6): 467-473. 10.1002/humu.1380010603.View ArticlePubMedGoogle Scholar
- Nakamura Y, Nishisho I, Kinzler KW, Vogelstein B, Miyoshi Y, Miki Y, Ando H, Horii A: Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial polyposis coli) patients and in sporadic colorectal tumors. Tohoku J Exp Med. 1992, 168 (2): 141-147. 10.1620/tjem.168.141.View ArticlePubMedGoogle Scholar
- Abraham SC, Reynolds C, Lee JH, Montgomery EA, Baisden BL, Krasinskas AM, Wu TT: Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol. 2002, 33 (1): 39-46. 10.1053/hupa.2002.30196.View ArticlePubMedGoogle Scholar
- Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ: Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999, 18 (47): 6615-6620. 10.1038/sj.onc.1203041.View ArticlePubMedGoogle Scholar
- Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K: The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg [Am]. 1996, 21 (2): 210-215. 10.1016/S0363-5023(96)80102-X.View ArticleGoogle Scholar
- Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D: TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J. 1995, 27 (12): 1014-1020.View ArticlePubMedGoogle Scholar
- Cheon SS, Nadesan P, Poon R, Alman BA: Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res. 2004, 293 (2): 267-274. 10.1016/j.yexcr.2003.09.029.View ArticlePubMedGoogle Scholar
- Cheon SS, Wei Q, Gurung A, Youn A, Bright T, Poon R, Whetstone H, Guha A, Alman BA: Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing. Faseb J. 2006, 20 (6): 692-701. 10.1096/fj.05-4759com.View ArticlePubMedGoogle Scholar
- Amini Nik S, Ebrahim RP, Van Dam K, Cassiman JJ, Tejpar S: TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations. Exp Cell Res. 2007, 313 (13): 2887-2895. 10.1016/j.yexcr.2007.05.024.View ArticlePubMedGoogle Scholar
- Bisson MA, McGrouther DA, Mudera V, Grobbelaar AO: The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J Hand Surg [Br]. 2003, 28 (4): 351-356.View ArticleGoogle Scholar
- Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richards RS, McFarlane RM, Alman B, Howard JC: Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene. 2003, 22 (24): 3680-3684. 10.1038/sj.onc.1206415.View ArticlePubMedGoogle Scholar
- Howard JC, Varallo VM, Ross DC, Faber KJ, Roth JH, Seney S, Gan BS: Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. J Surg Res. 2004, 117 (2): 232-238. 10.1016/j.jss.2004.01.013.View ArticlePubMedGoogle Scholar
- Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B, Gan BS: Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet Disord. 2003, 4: 16-10.1186/1471-2474-4-16.View ArticlePubMedPubMed CentralGoogle Scholar
- Vidal Bde C: From collagen type I solution to fibers with a helical pattern: a self-assembly phenomenon. C R Acad Sci III. 1995, 318 (8): 831-836.PubMedGoogle Scholar
- Wong M, Mudera V: Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts. J Hand Surg [Br]. 2006, 31 (5): 473-483.View ArticleGoogle Scholar
- Dave SA, Banducci DR, Graham WP, Allison GM, Ehrlich HP: Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords. Exp Mol Pathol. 2001, 71 (2): 147-155. 10.1006/exmp.2001.2385.View ArticlePubMedGoogle Scholar
- Seyhan H, Kopp J, Schultze-Mosgau S, Horch RE: Increased metabolic activity of fibroblasts derived from cords compared with nodule fibroblasts sampling from patients with Dupuytren's contracture. Plast Reconstr Surg. 2006, 117 (4): 1248-1252. 10.1097/01.prs.0000204585.97844.7e.View ArticlePubMedGoogle Scholar
- Shih B, Wijeratne D, Armstrong DJ, Lindau T, Day P, Bayat A: Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg [Am]. 2009, 34 (1): 124-136. 10.1016/j.jhsa.2008.09.017.View ArticleGoogle Scholar
- Rajan N, Habermehl J, Cote MF, Doillon CJ, Mantovani D: Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications. Nat Protoc. 2006, 1 (6): 2753-2758. 10.1038/nprot.2006.430.View ArticlePubMedGoogle Scholar
- Shi Y, Rittman L, Vesely I: Novel geometries for tissue-engineered tendonous collagen constructs. Tissue Eng. 2006, 12 (9): 2601-2609. 10.1089/ten.2006.12.2601.View ArticlePubMedGoogle Scholar
- Brickley-Parsons D, Glimcher MJ, Smith RJ, Albin R, Adams JP: Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg [Am]. 1981, 63 (5): 787-797.Google Scholar
- Ottani V, Martini D, Franchi M, Ruggeri A, Raspanti M: Hierarchical structures in fibrillar collagens. Micron. 2002, 33 (7–8): 587-596. 10.1016/S0968-4328(02)00033-1.View ArticlePubMedGoogle Scholar
- Alioto RJ, Rosier RN, Burton RI, Puzas JE: Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. J Hand Surg [Am]. 1994, 19 (3): 442-452. 10.1016/0363-5023(94)90059-0.View ArticleGoogle Scholar
- Tomasek JJ, Vaughan MB, Haaksma CJ: Cellular structure and biology of Dupuytren's disease. Hand Clin. 1999, 15 (1): 21-34.PubMedGoogle Scholar
- Wipff PJ, Rifkin DB, Meister JJ, Hinz B: Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol. 2007, 179 (6): 1311-1323. 10.1083/jcb.200704042.View ArticlePubMedPubMed CentralGoogle Scholar
- Grotendorst GR, Rahmanie H, Duncan MR: Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. Faseb J. 2004, 18 (3): 469-479. 10.1096/fj.03-0699com.View ArticlePubMedGoogle Scholar
- Larsen M, Artym VV, Green JA, Yamada KM: The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol. 2006, 18 (5): 463-471. 10.1016/j.ceb.2006.08.009.View ArticlePubMedGoogle Scholar
- Wang JH, Thampatty BP, Lin JS, Im HJ: Mechanoregulation of gene expression in fibroblasts. Gene. 2007, 391 (1–2): 1-15. 10.1016/j.gene.2007.01.014.View ArticlePubMedPubMed CentralGoogle Scholar
- White LR, Blanchette JB, Ren L, Awn A, Trpkov K, Muruve DA: The characterization of alpha5-integrin expression on tubular epithelium during renal injury. Am J Physiol Renal Physiol. 2007, 292 (2): F567-576. 10.1152/ajprenal.00212.2006.View ArticlePubMedGoogle Scholar
- Zambruno G, Marchisio PC, Marconi A, Vaschieri C, Melchiori A, Giannetti A, De Luca M: Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol. 1995, 129 (3): 853-865. 10.1083/jcb.129.3.853.View ArticlePubMedGoogle Scholar
- Magro G, Fraggetta F, Travali S, Lanzafame S: Immunohistochemical expression and distribution of alpha2beta1, alpha6beta1, alpha5beta1 integrins and their extracellular ligands, type IV collagen, laminin and fibronectin in palmar fibromatosis. Gen Diagn Pathol. 1997, 143 (4): 203-208.PubMedGoogle Scholar
- Magro G, Lanzafame S, Micali G: Co-ordinate expression of alpha 5 beta 1 integrin and fibronectin in Dupuytren's disease. Acta Histochem. 1995, 97 (3): 229-233.View ArticlePubMedGoogle Scholar
- Koenig A, Mueller C, Hasel C, Adler G, Menke A: Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006, 66 (9): 4662-4671. 10.1158/0008-5472.CAN-05-2804.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/10/72/prepub